Physician profile
Erin E Considine
NPI 1932161882
$2,446.45
in general payments reported to CMS, 2019-2025
13 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $978 · 2020: $426 · 2022: $206 · 2024: $494 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $836.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $911.98 | 2019-2025 | |
| Novo Nordisk INC | $426.82 | 2019-2024 | Wegovy |
| Pfizer INC. | $304.71 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $246.58 | 2024 | Breztri, Airsupra |
| Abbvie INC. | $125.26 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.92 | 2019 | |
| Lilly USA, LLC | $107.10 | 2022 | |
| Evoke Pharma, INC. | $100.38 | 2025 | |
| Glaxosmithkline, LLC. | $27.57 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.24 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $20.17 | 2020 | |
| Astellas Pharma US INC | $16.60 | 2024 | Veozah |
| Amarin Pharma, INC. | $15.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Considine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.